中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2013年
7期
1397-1399,封3
,共4页
帕瑞昔布钠%骨密度%骨钙素%氯胺酮
帕瑞昔佈鈉%骨密度%骨鈣素%氯胺酮
파서석포납%골밀도%골개소%록알동
Parecoxib%Bone mineral density%Bone gla protein%Ketamine
目的 观察帕瑞昔布钠对大鼠骨代谢的影响及氯胺酮对其的干预作用.方法 将32只SD大鼠随机分为4组(n=8):对照组(Control组)、静脉麻醉药组(Ketamine组)、选择性环氧合酶-2(COX-2)抑制剂组(Parecoxib组)、静脉麻醉药预处理组(Keta+ Pare组).每日给药,早晚间隔12h,各1次,连续3d给药完成后7、14、35 d,分别测量骨密度及骨钙素.结果 7d时骨密度测量结果(g/cm2),各组间比较差异无统计学意义(F=1.802,P＞0.05)；14 d时骨密度测量结果,各组间比较差异无统计学意义(F=2.699,P ＞0.05)；35 cd时骨密度测量结果,以上各组分别为0.1444±0.0036、0.1426±0.0024、0.1377±0.0005以及0.1308±0.0066,各组间差异有统计学意义(F=15.258,P＜0.05),经LSD两两比较,选择性COX-2抑制剂组与其他组间差异有统计学意义(P＜0.05)；静脉麻醉药预处理组与其他各组之间差异有统计学意义(P＜0.05)；对照组及静脉麻醉药组组间差异无统计学意义(P ＞0.05) 7d时骨钙素测量结果(个/视野),以上各组分别为222.500±9.607、229.830±6.795、226.830±12.828以及115.830±11.125,静脉麻醉药预处理组与其他3组间差异有统计学意义(F=172.335,P ＜0.05)；14 d时骨钙素测量结果,以上各组分别为229.830±5.193、221.670±16.884、85.500±15.592以及223.670±34.256,选择性COX-2抑制剂组与其他3组差异有统计学意义(F=67.768,P＜0.05);35d时骨钙素测量结果,以上各组分别为231.170±72.486、221.000±51.166、100.500±14.053以及101.500±8.643,选择性COX-2抑制剂组及静脉麻醉药预处理组与对照组及静脉麻醉药组比较差异有统计学意义(F=15.420,P＜0.05).结论 使用帕瑞昔布钠对大鼠骨密度和骨钙素水平都产生了一定的抑制作用,对骨愈合产生不良影响,氯胺酮可能会发挥协同效应,加重这一过程.
目的 觀察帕瑞昔佈鈉對大鼠骨代謝的影響及氯胺酮對其的榦預作用.方法 將32隻SD大鼠隨機分為4組(n=8):對照組(Control組)、靜脈痳醉藥組(Ketamine組)、選擇性環氧閤酶-2(COX-2)抑製劑組(Parecoxib組)、靜脈痳醉藥預處理組(Keta+ Pare組).每日給藥,早晚間隔12h,各1次,連續3d給藥完成後7、14、35 d,分彆測量骨密度及骨鈣素.結果 7d時骨密度測量結果(g/cm2),各組間比較差異無統計學意義(F=1.802,P＞0.05)；14 d時骨密度測量結果,各組間比較差異無統計學意義(F=2.699,P ＞0.05)；35 cd時骨密度測量結果,以上各組分彆為0.1444±0.0036、0.1426±0.0024、0.1377±0.0005以及0.1308±0.0066,各組間差異有統計學意義(F=15.258,P＜0.05),經LSD兩兩比較,選擇性COX-2抑製劑組與其他組間差異有統計學意義(P＜0.05)；靜脈痳醉藥預處理組與其他各組之間差異有統計學意義(P＜0.05)；對照組及靜脈痳醉藥組組間差異無統計學意義(P ＞0.05) 7d時骨鈣素測量結果(箇/視野),以上各組分彆為222.500±9.607、229.830±6.795、226.830±12.828以及115.830±11.125,靜脈痳醉藥預處理組與其他3組間差異有統計學意義(F=172.335,P ＜0.05)；14 d時骨鈣素測量結果,以上各組分彆為229.830±5.193、221.670±16.884、85.500±15.592以及223.670±34.256,選擇性COX-2抑製劑組與其他3組差異有統計學意義(F=67.768,P＜0.05);35d時骨鈣素測量結果,以上各組分彆為231.170±72.486、221.000±51.166、100.500±14.053以及101.500±8.643,選擇性COX-2抑製劑組及靜脈痳醉藥預處理組與對照組及靜脈痳醉藥組比較差異有統計學意義(F=15.420,P＜0.05).結論 使用帕瑞昔佈鈉對大鼠骨密度和骨鈣素水平都產生瞭一定的抑製作用,對骨愈閤產生不良影響,氯胺酮可能會髮揮協同效應,加重這一過程.
목적 관찰파서석포납대대서골대사적영향급록알동대기적간예작용.방법 장32지SD대서수궤분위4조(n=8):대조조(Control조)、정맥마취약조(Ketamine조)、선택성배양합매-2(COX-2)억제제조(Parecoxib조)、정맥마취약예처리조(Keta+ Pare조).매일급약,조만간격12h,각1차,련속3d급약완성후7、14、35 d,분별측량골밀도급골개소.결과 7d시골밀도측량결과(g/cm2),각조간비교차이무통계학의의(F=1.802,P＞0.05)；14 d시골밀도측량결과,각조간비교차이무통계학의의(F=2.699,P ＞0.05)；35 cd시골밀도측량결과,이상각조분별위0.1444±0.0036、0.1426±0.0024、0.1377±0.0005이급0.1308±0.0066,각조간차이유통계학의의(F=15.258,P＜0.05),경LSD량량비교,선택성COX-2억제제조여기타조간차이유통계학의의(P＜0.05)；정맥마취약예처리조여기타각조지간차이유통계학의의(P＜0.05)；대조조급정맥마취약조조간차이무통계학의의(P ＞0.05) 7d시골개소측량결과(개/시야),이상각조분별위222.500±9.607、229.830±6.795、226.830±12.828이급115.830±11.125,정맥마취약예처리조여기타3조간차이유통계학의의(F=172.335,P ＜0.05)；14 d시골개소측량결과,이상각조분별위229.830±5.193、221.670±16.884、85.500±15.592이급223.670±34.256,선택성COX-2억제제조여기타3조차이유통계학의의(F=67.768,P＜0.05);35d시골개소측량결과,이상각조분별위231.170±72.486、221.000±51.166、100.500±14.053이급101.500±8.643,선택성COX-2억제제조급정맥마취약예처리조여대조조급정맥마취약조비교차이유통계학의의(F=15.420,P＜0.05).결론 사용파서석포납대대서골밀도화골개소수평도산생료일정적억제작용,대골유합산생불량영향,록알동가능회발휘협동효응,가중저일과정.
Objective To study the effects of parecoxib on bone metabolism of rats at different time points,and intervention of ketamine.Methods Thirty-two SD rats were randomly divided into four groups:control group,ketamine group,parecoxib group,ketamine + parecoxib group.The treatments were given once every 12 h for three days.After being finished doses for seven days,fourteen days and thirty-five days,bone mineral density (BMD) & osteocalcin (BGP) measurements would be separately taken.Results Result of seven-day BMD measurement:It was not statistically significant between the different groups (F =I.802,P ＞ 0.05).Result of fourteen-day BMD measurement:It was not statistically significant between the different groups (F =2.699,P ＞ 0.05).Result of thirty-five-day BMD measurement:Each of them were 0.1444 ±0.0036,0.1426 ± 0.0024,0.1377 ± 0.0005 and 0.1308 ± 0.0066,It was showed statistically significant between the different groups (F =15.258,P ＜ 0.05).By comparison,It was showed statistically significant between the different of precoxib group and others;It was showed statistically significant between the different of ketamine group and others,too;Meanwhile,It was not statistically significant between control group and ketamine group.Result of seven-day BGP measurement:Each of them were 222.500 ± 9.607,229.830 ±6.795,226.830 ± 12.828 and 115.830 ± 11.125,It was showed statistically significant between the different of ketamine group and others (F =172.335,P ＜ 0.05).Result of fourteen-day BGP measurement:Each of them were 229.830 ±5.193,221.670 ± 16.884,85.500 ± 15.592 and 223.670 ±34.256,It was showed statistically significant between the different of precoxib group and others (F =67.768,P ＜0.05).Result of thirty-five-day BGP measurement:Each of them were 231.170 ± 72.486,221.000 ±51.166,100.500 ± 14.053 and 101.500 ± 8.643,It was showed statistically significant between the different precoxib group& ketamine group and control group & ketamine group (F =15.420,P ＜0.05).Conclusion The use of parecoxib weakened BMD and BGP,and had an adverse impact on symphysis.The process may be accelerated after using ketamine.
